Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in:

Open Access 01-12-2024 | Ovarian Cancer | Correspondence

A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy

Authors: Xiumin Li, Xudong Wang, Hao Wang, Donghua Zuo, Jianpo Xu, Yixuan Feng, Dixuan Xue, Li Zhang, Lin Lin, Jin Zhang

Published in: Journal of Hematology & Oncology | Issue 1/2024

Login to get access

Abstract

CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual roles in phagocytosis and immune modulation. Here we show the clinical results of CAR-macrophage treatment of two ovarian cancer patients. The CAR-macrophages were produced by introducing a mesothelin targeting CAR to patients’ primary peripheral blood mononuclear cell-derived macrophages, and the products were infused to patients intravenously. Our data show good safety of the infusion product, and the efficacy can be further improved. Intraperitoneal infusion of CAR-macrophages has proven effective in treating intraperitoneal tumors in a preclinical model, paving the way for demonstrating proof-of-concept clinical efficacy of CAR-macrophages in the treatment of intraperitoneal tumors.
Appendix
Available only for authorised users
Literature
1.
Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239–57.CrossRefPubMed
2.
Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21(1):47–66.CrossRefPubMed
3.
Goswami S, et al. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2023;23(2):106–20.CrossRefPubMed
4.
5.
6.
Wang X, et al. Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. Nat Commun. 2023;14(1):5778.CrossRefPubMedPubMedCentral
7.
Zhou C, et al. Transfer of cGAMP into bystander cells via LRRC8 volume-regulated Anion channels augments STING-Mediated Interferon responses and anti-viral immunity. Immunity. 2020;52(5):767–e7816.CrossRefPubMed
Metadata
Title
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy
Authors
Xiumin Li
Xudong Wang
Hao Wang
Donghua Zuo
Jianpo Xu
Yixuan Feng
Dixuan Xue
Li Zhang
Lin Lin
Jin Zhang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2024
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-024-01635-5

Other articles of this Issue 1/2024

Decoding the glycoproteome: a new frontier for biomarker discovery in cancer

Landscape of biallelic DNMT3A mutant myeloid neoplasms

c-Myc alone is enough to reprogram fibroblasts into functional macrophages

Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears

Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives

Targeting GPRC5D for multiple myeloma therapy

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits